Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Cervical Cancer: Screening and Treatment in 2026
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cervical Cancer: Screening and Treatment in 2026

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 August 2026 | Viewed by 1500

Special Issue Editors

Dr. Benedetta Guani

E-Mail Website
Guest Editor
Gynecologic Department, CHU Vaudois, 1011 Lausanne, Switzerland
Interests: endometrial cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Fabrice Lécuru

E-Mail Website
Guest Editor
Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, Paris University, F-75005 Paris, France
Interests: cervical cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the new edition of the issue “Cervical Cancer: Screening and Treatment in 2024-2025”, available at https://www.mdpi.com/journal/cancers/special_issues/0UDBR4M51X.

With nearly 570,000 new cases per year and 310,000 deaths per year, cervical cancer remains a significant cause of morbidity and mortality worldwide, particularly in developing countries without widespread screening programs. Many cervical cancer patients are young and still in their childbearing years, emphasizing the crucial need for early diagnosis to enable fertility-sparing treatment.

In instances of locally advanced stages, ongoing research aims to optimize treatment approaches.

We are delighted to invite you to contribute to this Special Issue on cervical cancer.

This Special Issue intends to achieve the following:

  1. Delve into primary and secondary screening, exploring indications and treatments for fertility preservation in 2026.
  2. Examine treatment modalities for early and locally advanced stages, with a focus on staging lymphadenectomy, immunotherapy, and targeted therapies.

We welcome original research articles and reviews in this Special Issue, encompassing research areas such as screening, fertility preservation in early-stage cervical cancer patients, and treatment for locally advanced cervical cancer, including immunotherapy and targeted therapies.

We look forward to hearing from you.

Dr. Benedetta Guani
Dr. Fabrice Lécuru
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • fertility sparing
  • screening
  • early stage cervical cancer
  • locally advanced cervical cancer
  • sentinel lymph node
  • staging lymphadenectomy
  • trachelectomy
  • immunotherapy in cervical cancer
  • target therapy in cervical cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 953 KB  
Article
Prognostic Survival Model Following Primary Radical Surgery for Early-Stage Cervical Cancer
by Rattiya Phianpiset, Chayanid Detwongya, Manatsawee Manopunya, Chalong Cheewakriangkrai and Kittipat Charoenkwan
Cancers 2026, 18(7), 1134; https://doi.org/10.3390/cancers18071134 - 1 Apr 2026
Viewed by 576
Abstract
Background: Radical hysterectomy with pelvic lymphadenectomy is a standard surgical procedure for early-stage cervical cancer. However, even with optimal treatment, some patients still experience disease recurrence. We aimed to develop and validate a prediction model to classify patients according to the risk [...] Read more.
Background: Radical hysterectomy with pelvic lymphadenectomy is a standard surgical procedure for early-stage cervical cancer. However, even with optimal treatment, some patients still experience disease recurrence. We aimed to develop and validate a prediction model to classify patients according to the risk of recurrence which can better assist clinicians to tailor the postoperative treatment and improve patient outcomes. Methods: Data of women diagnosed with early-stage cervical cancer who underwent radical hysterectomy were collected and analyzed. The primary outcome was recurrence-free survival (RFS). A prediction model based on Cox proportional hazard regression was developed by using the backward elimination procedure. Internal validation was performed by bootstrapping. The model’s discriminative ability was demonstrated by the concordance index (C-index). The model’s calibration was examined through a calibration plot. The final prognostic model was presented as a nomogram and a web-based calculator, which were further used to categorize patients into low, moderate, and high-risk groups for clinical application. Results: Among the 1309 patients, 115 (8.8%) experienced a recurrence. The median follow-up was 72.2 months. The 3-year and 5-year RFS rates were 93.0% (95% CI, 91.5–94.6%) and 90.7% (95% CI, 88.9–92.5%), respectively. Tumor size, histological subtype, number of positive lymph nodes, lymphovascular space invasion, and platelet-to-lymphocyte ratio were significantly associated with RFS. These factors were employed to construct a prediction model. The model exhibited a good overall fit with minimal overfitting and good calibration. The model’s discriminative performance, as measured by the C-index, was 0.73. Conclusions: Our proposed survival model offers a potentially valuable tool for therapeutic decision-making in patients with early-stage cervical cancer. This model demonstrates robust discriminative performance and predictive calibration. Nevertheless, external validation across diverse datasets should be conducted to assess the reproducibility and applicability of this predictive model across a broader spectrum of patients. Full article
(This article belongs to the Special Issue Cervical Cancer: Screening and Treatment in 2026)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 498 KB  
Review
Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review
by Claire Meynard, Emmanuel Fardeau, Tiphaine Lambert, Sophie Guillerm, Diane Jornet, Laurent Quero and Christophe Hennequin
Cancers 2026, 18(9), 1409; https://doi.org/10.3390/cancers18091409 - 29 Apr 2026
Viewed by 531
Abstract
The treatment of locally advanced cervical cancer is based on concomitant cisplatin-based chemoradiotherapy followed by brachytherapy. The quality of this treatment is essential to optimize results. In particular, intensity-modulated radiotherapy followed by image-guided brachytherapy achieves 90% local control regardless of the stage of [...] Read more.
The treatment of locally advanced cervical cancer is based on concomitant cisplatin-based chemoradiotherapy followed by brachytherapy. The quality of this treatment is essential to optimize results. In particular, intensity-modulated radiotherapy followed by image-guided brachytherapy achieves 90% local control regardless of the stage of the disease. More recently, several randomized trials have changed the management of these tumors: The INTERLACE trial evaluated the benefits of neoadjuvant chemotherapy with carboplatin and paclitaxel and demonstrated a survival benefit for this approach. This trial has been the subject of considerable criticism. The KEYNOTE A.18 trial evaluated the addition of pembrolizumab to standard treatment: an improvement in overall survival was demonstrated for patients with stage III-IV disease (FIGO 2014 classification). The CALLA trial, which evaluated the addition of durvalumab, was negative. This review summarizes the biological rationale for this immunotherapy, its results, and the quality criteria for chemoradiotherapy. It describes the various trials in detail, puts their results into context, and discusses the relevance of this new treatment based on the patients’ baseline characteristics. Based on this critical analysis, patients with stage III-IVA cervical cancer (FIGO 2014 classification) should receive, in addition to standard chemoradiotherapy, concomitant treatment with pembrolizumab followed by two years of maintenance therapy. Full article
(This article belongs to the Special Issue Cervical Cancer: Screening and Treatment in 2026)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop